Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever
- 764 Downloads
Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1–4) and 12 (4–50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.
KEY WORDSfamilial Mediterranean fever colchicine anakinra canakinumab rilonacept interleukin-1 receptor antagonist protein amyloidosis
Conflict of Interest
There are no conflicts of interest for any of the authors.
- 6.Hashkes, P.J., S.J. Spalding, E.H. Giannini, B. Huang, A. Johnson, G. Park, K.S. Barron, M.H. Weisman, N. Pashinian, A.O. Reiff, et al. 2012. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: A randomized trial. Annals of Internal Medicine 157(8): 533–541.CrossRefPubMedGoogle Scholar
- 9.Stankovic Stojanovic, K., Y. Delmas, P.U. Torres, J. Peltier, G. Pelle, I. Jeru, M. Colombat, and G. Grateau. 2012. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrology, Dialysis, Transplantation 27(5): 1898–1901.CrossRefPubMedGoogle Scholar